Table 1: Currently available DAA agents, common adverse events, renal and hepatic function considerations.

Drug

Brand Name

HCV genotype

Adverse Event Reported > 10%

Renal function
limits

Hepatic function
limits

Simeprevir

Olysio®

1 when combined with sofosbuvir

Photosensitivity, fatigue, headache, dizziness, insomnia, nausea, increased bilirubin, diarrhea, myalgia, dyspnea

None

Avoid in decompensated cirrhosis or Child-Pugh B or C

Sofosbuvir

Sovaldi®

1 when combined with ledipasvir, 3 when combined with daclatasvir

Fatigue, nausea, headache, insomnia, weakness

Not recommended
for CrCl < 30 ml/min

None

Ledipasvir/Sofosbuvir

Harvoni®

1 and 4

Headache, fatigue, insomnia

Not recommended
for CrCl < 30 ml/min

None

Ombitasvir/Paritaprevir
Ritonavir/Dasabuvir

Viekira Pak™
Viekira XRTM

1

Fatigue, headache, insomnia, rash, pruritis, diarrhea, nausea, anemia, increased bilirubin,
increased ALT, weakness, muscle spasm, cough

None

Avoid in decompensated cirrhosis or Child-Pugh B or C

Daclatasvir

Daklinza™

3 when combined with sofosbuvir

Fatigue, nausea, headache, anemia

None

None

Ombitasvir/Paritaprevir
Ritonavir

Technivie™

4

Fatigue, insomnia, rash, pruritis,  nausea, increased ALT, anemia

None

Avoid in decompensated cirrhosis or Child-Pugh B or C

Elbasvir/Grazoprevir

Zepatier™

1 & 4

Fatigue, headache, nausea

None

Avoid in decompensated cirrhosis or Child-Pugh B or C

Sofosbuvir/Velpatasvir

Epclusa®

1,2,3,4,5 & 6

Headache, fatigue

Not recommended
for CrCl < 30 ml/min

None

Data obtained from product package insert [27,33,34,46-51].